Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: LZIC (ImmuneEditome ID:84328)

1. Gene summary of enriched editing regions for LZIC

Gene summary

Gene information	Gene symbol	LZIC
	Gene ID	84328
	GeneSynonyms	-
	GeneCytomap	1p36.22
	GeneType	protein-coding
	GeneDescription	protein LZIC\|leucine zipper and CTNNBIP1 domain-containing protein\|leucine zipper and ICAT homologous domain-containing protein\|leucine zipper domain and ICAT homologous domain containing
	GeneModificationdate	20230329
	UniprotID	Q8WZA0;K7ES95;A0A024R4I7
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr1:9927315-9928868:-	ENST00000488540.4	ENSG00000162441.10	LZIC	intronic	AluSx3,AluSx,L1MB5,(ACA)n,AluSp	chr1:9927315-9928868:-.alignment

Top

2. Tumor-specific enriched editing regions for LZIC

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr1:9927315-9928868:-	BRCA	EER	6.1323e-04
ENSG00000162441.10,LZIC	BRCA	EAG	2.8775e-03
chr1:9927315-9928868:-	COAD	EER	2.2725e-14
ENSG00000162441.10,LZIC	COAD	EAG	3.5156e-14
chr1:9927315-9928868:-	KIRP	EER	1.1887e-04
ENSG00000162441.10,LZIC	KIRP	EAG	1.1116e-04
ENSG00000162441.10,LZIC	LIHC	EAG	1.4890e-02
chr1:9927315-9928868:-	LUSC	EER	3.4737e-03
ENSG00000162441.10,LZIC	LUSC	EAG	8.3724e-03
chr1:9927315-9928868:-	UCEC	EER	8.3962e-07
ENSG00000162441.10,LZIC	UCEC	EAG	1.1950e-06

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr1:9927315-9928868:-	LIHC	Path	EER	8.0575e-03	1.0146e-02	-0.1438
ENSG00000162441.10,LZIC	OV	Cli	EAG	4.2017e-02	9.0001e-03	0.1347

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr1:9927315-9928868:-	BRCA	EER	1.2556e-02	3.3652e-02	8.1591e-04

Top

3. Enriched editing regions and immune related genes for LZIC

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr1:9927315-9928868:-

UCEC

EER

ENSG00000111011,RSRC2

-0.4511

1.7845e-05

3.1563e-08

-0.4132

CSTF2T;EIF4A3;FBL;FUS;HNRNPK;PTBP1;RBFOX2;TAF15;IGF2BP2;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr1:9927315-9928868:-

UCEC

EER

ENSG00000215301,DDX3X

-0.4337

5.7386e-05

4.3039e-08

-0.4095

CSTF2T;DKC1;EIF4A3;FBL;FUS;HNRNPK;PTBP1;RBFOX2;TAF15;IGF2BP2;U2AF2

DDX3X

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr1:9927315-9928868:-

UCEC

EER

ENSG00000145907,G3BP1

-0.4274

9.0130e-05

7.3887e-08

-0.4029

CSTF2T;DKC1;EIF4A3;FBL;FUS;HNRNPK;PTBP1;RBFOX2;TAF15;IGF2BP2;U2AF2

G3BP1

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr1:9927315-9928868:-

UCEC

EER

ENSG00000226499,RP5-882O7.1

0.4259

9.3654e-05

1.8137e-08

0.4197

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

chr1:9927315-9928868:-

UCEC

EER

ENSG00000152942,RAD17

-0.4223

1.1067e-04

2.3413e-08

-0.4167

CSTF2T;DKC1;EIF4A3;FBL;FUS;HNRNPK;PTBP1;RBFOX2;TAF15;IGF2BP2;U2AF2

Eosinophils

GSVA_HALLMARK_MITOTIC_SPINDLE

chr1:9927315-9928868:-

UCEC

EER

ENSG00000138069,RAB1A

-0.4190

1.3327e-04

2.5859e-08

-0.4156

CSTF2T;DKC1;EIF4A3;FBL;FUS;HNRNPK;PTBP1;RBFOX2;TAF15;IGF2BP2;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

chr1:9927315-9928868:-

UCEC

EER

ENSG00000227077,AC107983.4

0.4126

1.9255e-04

1.3917e-21

0.6535

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

chr1:9927315-9928868:-

UCEC

EER

ENSG00000237214,RP11-12M9.3

0.3991

3.6831e-04

6.6091e-22

0.6574

T_cells_CD4_memory_resting

GSVA_HALLMARK_UV_RESPONSE_DN

chr1:9927315-9928868:-

UCEC

EER

ENSG00000166478,ZNF143

-0.3981

3.7668e-04

3.3410e-08

-0.4125

CSTF2T;DKC1;EIF4A3;FBL;FUS;HNRNPK;PTBP1;RBFOX2;TAF15;IGF2BP2;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_PROTEIN_SECRETION

chr1:9927315-9928868:-

UCEC

EER

ENSG00000229119,CTB-63M22.1

0.3908

5.1976e-04

3.4256e-08

0.4122

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

More results

Top

4. Enriched editing regions and immune related splicing for LZIC

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000162441.10,LZIC

UCEC

EAG

MEX

ENSG00000182240.11

chr21

41167800:41168575:41226265:41226354:41257157:41257326:41275370:41275381

-0.3730

4.6990e-03

4.2741e-08

-0.4073

ACIN1;ADAR;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FBL;FMR1;FUS;FXR2;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LIN28;LIN28A;LIN28B;MBNL2;METTL3;MOV10;MSI1;NOP56;NOP58;PTBP1;QKI;RANGAP1;RBFOX2;RBM47;RBM5;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIAL1;U2AF2;UPF1;VIM;ZC3H7B

T_cells_CD4_memory_resting

GSVA_HALLMARK_UV_RESPONSE_DN

chr1:9927315-9928868:-

UCEC

EER

ENSG00000142208.11

chr14

104770744:104770823:104769391:104769626:104769391:104770420

0.3291

3.2704e-02

1.0159e-12

0.5168

CSTF2T;DKC1;EIF4A3;FBL;FUS;HNRNPK;PTBP1;RBFOX2;TAF15;IGF2BP2;U2AF2

AKT1

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

ENSG00000162441.10,LZIC

UCEC

EAG

MEX

ENSG00000178719.12

chr8

143991746:143991804:143991877:143991949:143991955:143992078:143992244:143992373

-0.3405

1.8453e-02

3.0670e-12

-0.5033

ACIN1;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RBM47;RBM5;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr1:9927315-9928868:-

UCEC

EER

MEX

ENSG00000042493.11

chr2

85394894:85394958:85395537:85395626:85399180:85399285:85401164:85401257

0.3728

6.6654e-03

9.9083e-11

0.4752

CSTF2T;DKC1;EIF4A3;FBL;FUS;HNRNPK;PTBP1;RBFOX2;TAF15;IGF2BP2;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr1:9927315-9928868:-

UCEC

EER

MEX

ENSG00000105053.6

chr19

49989695:49989771:49992859:49992952:49997503:49997570:50000789:50000854

0.3469

1.6111e-02

4.4075e-09

0.4370

CSTF2T;DKC1;EIF4A3;FBL;FUS;HNRNPK;PTBP1;RBFOX2;TAF15;IGF2BP2;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_UV_RESPONSE_DN

chr1:9927315-9928868:-

UCEC

EER

MEX

ENSG00000150991.10

chr12

124911647:124911822:124911952:124912734:124912734:124912772:124912962:124913039

-0.4065

1.3732e-03

7.2683e-09

-0.4302

CSTF2T;EIF4A3;FBL;FUS;HNRNPK;PTBP1;RBFOX2;TAF15;IGF2BP2;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_PROTEIN_SECRETION

chr1:9927315-9928868:-

UCEC

EER

MEX

ENSG00000108010.7

chr10

130160795:130160997:130166506:130166586:130174866:130174906:130174996:130175089

-0.3721

6.6760e-03

1.2986e-11

-0.4943

CSTF2T;DKC1;EIF4A3;FBL;FUS;HNRNPK;PTBP1;RBFOX2;TAF15;IGF2BP2;U2AF2

GLRX3

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000162441.10,LZIC

UCEC

EAG

MEX

ENSG00000134291.7

chr12

47964280:47964423:47965281:47965345:47967207:47967261:47968132:47968171

-0.3737

4.9189e-03

2.5882e-09

-0.4392

BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RC3H1;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;ZC3H7B;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

chr1:9927315-9928868:-

UCEC

EER

MEX

ENSG00000178467.13

chr3

49002499:49002596:49004097:49004260:49006063:49006187:49006686:49007115

-0.4047

1.4067e-03

3.6069e-08

-0.4116

CSTF2T;DKC1;EIF4A3;FBL;FUS;HNRNPK;PTBP1;RBFOX2;TAF15;IGF2BP2;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000162441.10,LZIC

UCEC

EAG

ENSG00000117862.7

chr1

52020130:52020405:52020925:52021012

-0.3561

1.0748e-02

1.1632e-08

-0.4225

ACIN1;ADAR;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZC3H7B;ZNF184

T_cells_CD4_memory_resting

GSVA_HALLMARK_PROTEIN_SECRETION

More results

Top

5. Enriched editing regions and immune infiltration for LZIC

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr1:9927315-9928868:-	ACC	EER	Macrophages_M2	3.9804e-02	0.2396
ENSG00000162441.10,LZIC	ACC	EAG	Macrophages_M2	4.1849e-02	0.2372
chr1:9927315-9928868:-	BLCA	EER	T_cells_CD4_memory_activated	4.6119e-04	0.1748
ENSG00000162441.10,LZIC	BLCA	EAG	Macrophages_M1	2.6733e-03	0.1500
chr1:9927315-9928868:-	BRCA	EER	NK_cells_activated	1.6935e-06	0.1451
ENSG00000162441.10,LZIC	BRCA	EAG	NK_cells_activated	1.7223e-05	0.1303
chr1:9927315-9928868:-	CESC	EER	Macrophages_M2	4.8567e-02	0.1144
ENSG00000162441.10,LZIC	CESC	EAG	Macrophages_M2	3.9962e-02	0.1189
chr1:9927315-9928868:-	CHOL	EER	Macrophages_M1	4.4419e-02	0.3577
ENSG00000162441.10,LZIC	CHOL	EAG	Macrophages_M1	4.1993e-02	0.3616
chr1:9927315-9928868:-	COAD	EER	Macrophages_M0	2.9166e-02	-0.1328
ENSG00000162441.10,LZIC	COAD	EAG	Macrophages_M0	2.7908e-02	-0.1336
ENSG00000162441.10,LZIC	DLBC	EAG	Macrophages_M2	2.7041e-02	0.3372
chr1:9927315-9928868:-	ESCA	EER	T_cells_CD4_memory_resting	4.9295e-02	-0.1552
chr1:9927315-9928868:-	GBM	EER	Macrophages_M1	3.0930e-03	0.2276
ENSG00000162441.10,LZIC	GBM	EAG	Macrophages_M1	2.5761e-03	0.2318
chr1:9927315-9928868:-	HNSC	EER	Mast_cells_resting	8.2053e-03	-0.1193
ENSG00000162441.10,LZIC	HNSC	EAG	Neutrophils	6.6804e-03	0.1223
chr1:9927315-9928868:-	KIRC	EER	T_cells_regulatory_(Tregs)	2.9180e-04	0.1846
ENSG00000162441.10,LZIC	KIRC	EAG	T_cells_regulatory_(Tregs)	4.4065e-04	0.1792
chr1:9927315-9928868:-	LAML	EER	Eosinophils	1.7469e-02	0.2106
ENSG00000162441.10,LZIC	LAML	EAG	Eosinophils	1.7469e-02	0.2106
chr1:9927315-9928868:-	LGG	EER	T_cells_CD4_memory_activated	5.9881e-03	0.1195
ENSG00000162441.10,LZIC	LGG	EAG	T_cells_CD4_memory_activated	5.4983e-03	0.1207
chr1:9927315-9928868:-	LIHC	EER	T_cells_CD4_memory_resting	1.0015e-03	0.1772
ENSG00000162441.10,LZIC	LIHC	EAG	T_cells_CD4_memory_resting	5.1763e-04	0.1857
chr1:9927315-9928868:-	LUAD	EER	T_cells_gamma_delta	7.7968e-03	0.1184
ENSG00000162441.10,LZIC	LUAD	EAG	T_cells_gamma_delta	7.0318e-03	0.1197
chr1:9927315-9928868:-	MESO	EER	Dendritic_cells_activated	6.2614e-03	0.2995
ENSG00000162441.10,LZIC	MESO	EAG	Dendritic_cells_activated	3.6973e-02	0.2308
chr1:9927315-9928868:-	OV	EER	Macrophages_M1	3.6307e-05	0.2392
ENSG00000162441.10,LZIC	OV	EAG	Macrophages_M1	1.9189e-04	0.2166
chr1:9927315-9928868:-	PAAD	EER	Dendritic_cells_activated	3.9549e-03	0.2180
ENSG00000162441.10,LZIC	PAAD	EAG	Dendritic_cells_activated	4.8602e-03	0.2132
chr1:9927315-9928868:-	PCPG	EER	NK_cells_resting	1.1011e-02	0.1918
ENSG00000162441.10,LZIC	PCPG	EAG	NK_cells_resting	1.3393e-02	0.1866
chr1:9927315-9928868:-	PRAD	EER	B_cells_memory	4.5101e-04	0.1568
ENSG00000162441.10,LZIC	PRAD	EAG	B_cells_memory	4.1510e-04	0.1576
chr1:9927315-9928868:-	SARC	EER	T_cells_CD4_memory_resting	6.4217e-03	-0.1703
ENSG00000162441.10,LZIC	SARC	EAG	T_cells_CD4_memory_resting	5.0816e-03	-0.1750
chr1:9927315-9928868:-	SKCM	EER	T_cells_CD4_naive	1.9487e-02	0.1084
ENSG00000162441.10,LZIC	SKCM	EAG	T_cells_CD4_naive	1.6948e-02	0.1108
chr1:9927315-9928868:-	STAD	EER	T_cells_gamma_delta	1.3090e-03	0.1669
ENSG00000162441.10,LZIC	STAD	EAG	T_cells_gamma_delta	2.9034e-03	0.1548
chr1:9927315-9928868:-	TGCT	EER	Macrophages_M2	1.1380e-02	-0.2075
ENSG00000162441.10,LZIC	TGCT	EAG	Macrophages_M2	1.5226e-02	-0.1985
chr1:9927315-9928868:-	THCA	EER	T_cells_regulatory_(Tregs)	8.8453e-03	0.1171
ENSG00000162441.10,LZIC	THCA	EAG	Plasma_cells	1.6544e-02	0.1072
chr1:9927315-9928868:-	THYM	EER	Macrophages_M0	3.9452e-03	0.2680
ENSG00000162441.10,LZIC	THYM	EAG	T_cells_CD4_memory_activated	4.6993e-03	0.2619
chr1:9927315-9928868:-	UVM	EER	T_cells_follicular_helper	4.6669e-02	-0.2245
ENSG00000162441.10,LZIC	UVM	EAG	T_cells_follicular_helper	4.8337e-02	-0.2229

Top

6. Enriched editing regions and immune gene sets for LZIC

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
ENSG00000162441.10,LZIC	LIHC	EAG	3.3828e-03	-0.1571	2.5085e-04	-0.1956	3.9649e-03	-0.1545	1.5956e-02	0.1295
chr1:9927315-9928868:-	LIHC	EER	4.4883e-04	-0.1888	6.9905e-06	-0.2403	1.3222e-04	-0.2052	1.1271e-02	0.1369

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr1:9927315-9928868:-	ACC	GSVA_HALLMARK_PROTEIN_SECRETION	EER	6.3729e-04	-0.3880
ENSG00000162441.10,LZIC	ACC	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	4.0219e-04	-0.4008
ENSG00000162441.10,LZIC	BLCA	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	5.8045e-04	0.1715
chr1:9927315-9928868:-	BLCA	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	1.9391e-04	0.1858
chr1:9927315-9928868:-	BRCA	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	1.6580e-04	-0.1144
ENSG00000162441.10,LZIC	BRCA	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.4950e-03	0.0965
chr1:9927315-9928868:-	CESC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	7.3022e-04	0.1946
ENSG00000162441.10,LZIC	CESC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	1.5573e-03	0.1822
chr1:9927315-9928868:-	COAD	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	2.2847e-02	-0.1385
chr1:9927315-9928868:-	DLBC	GSVA_HALLMARK_DNA_REPAIR	EER	1.6862e-03	0.4648
ENSG00000162441.10,LZIC	DLBC	GSVA_HALLMARK_DNA_REPAIR	EAG	8.4589e-03	0.3966
ENSG00000162441.10,LZIC	ESCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	4.0456e-04	0.2755
chr1:9927315-9928868:-	ESCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.6760e-04	0.2835
chr1:9927315-9928868:-	GBM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	7.6758e-08	0.4013
ENSG00000162441.10,LZIC	GBM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	6.7822e-08	0.4028
ENSG00000162441.10,LZIC	HNSC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	2.2920e-04	-0.1655
chr1:9927315-9928868:-	HNSC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	2.7648e-05	-0.1882
chr1:9927315-9928868:-	KIRC	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	1.8230e-06	-0.2416
ENSG00000162441.10,LZIC	KIRC	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	4.1398e-06	-0.2334
ENSG00000162441.10,LZIC	KIRP	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.0601e-03	-0.1971
chr1:9927315-9928868:-	KIRP	GSVA_HALLMARK_PROTEIN_SECRETION	EER	1.3947e-03	-0.1925
ENSG00000162441.10,LZIC	LAML	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	1.0846e-02	-0.2254
chr1:9927315-9928868:-	LAML	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	1.0846e-02	-0.2254
ENSG00000162441.10,LZIC	LGG	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	3.7418e-07	-0.2190
chr1:9927315-9928868:-	LGG	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	4.5089e-07	-0.2175
chr1:9927315-9928868:-	LIHC	GSVA_HALLMARK_COAGULATION	EER	5.2804e-07	0.2672
ENSG00000162441.10,LZIC	LIHC	GSVA_HALLMARK_COAGULATION	EAG	6.6705e-05	0.2127
ENSG00000162441.10,LZIC	LUAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	3.4682e-03	0.1297
chr1:9927315-9928868:-	LUAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	2.4410e-03	0.1347
chr1:9927315-9928868:-	LUSC	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	4.2122e-02	-0.0918
ENSG00000162441.10,LZIC	LUSC	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	4.2052e-02	-0.0919
chr1:9927315-9928868:-	MESO	GSVA_HALLMARK_UV_RESPONSE_DN	EER	4.8598e-03	-0.3081
ENSG00000162441.10,LZIC	MESO	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	3.3608e-03	-0.3202
ENSG00000162441.10,LZIC	OV	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	4.1747e-07	0.2910
chr1:9927315-9928868:-	OV	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	3.7004e-07	0.2922
ENSG00000162441.10,LZIC	PAAD	GSVA_HALLMARK_P53_PATHWAY	EAG	1.0800e-03	0.2465
chr1:9927315-9928868:-	PAAD	GSVA_HALLMARK_P53_PATHWAY	EER	8.0948e-04	0.2524
ENSG00000162441.10,LZIC	PCPG	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	8.4979e-03	-0.1984
chr1:9927315-9928868:-	PCPG	GSVA_HALLMARK_MYC_TARGETS_V1	EER	5.9406e-03	-0.2072
ENSG00000162441.10,LZIC	PRAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	1.4898e-03	-0.1420
chr1:9927315-9928868:-	PRAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	3.2087e-03	-0.1320
ENSG00000162441.10,LZIC	READ	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	5.0816e-03	0.2867
chr1:9927315-9928868:-	READ	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	4.1894e-03	0.2928
chr1:9927315-9928868:-	SARC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	5.2985e-04	-0.2155
ENSG00000162441.10,LZIC	SARC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.6803e-04	-0.2335
chr1:9927315-9928868:-	SKCM	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	1.1747e-12	-0.3220
ENSG00000162441.10,LZIC	SKCM	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	1.6164e-12	-0.3201
ENSG00000162441.10,LZIC	STAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.5267e-02	-0.1264
chr1:9927315-9928868:-	STAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	1.2972e-02	-0.1294
chr1:9927315-9928868:-	TGCT	GSVA_HALLMARK_SPERMATOGENESIS	EER	5.8357e-03	0.2256
ENSG00000162441.10,LZIC	TGCT	GSVA_HALLMARK_SPERMATOGENESIS	EAG	6.7839e-03	0.2209
chr1:9927315-9928868:-	THCA	GSVA_HALLMARK_UV_RESPONSE_DN	EER	3.7722e-06	-0.2053
ENSG00000162441.10,LZIC	THCA	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	5.2392e-06	-0.2023
ENSG00000162441.10,LZIC	THYM	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	1.8197e-03	0.2877
chr1:9927315-9928868:-	THYM	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	1.1180e-03	0.3014
ENSG00000162441.10,LZIC	UCEC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.9114e-04	-0.2832
chr1:9927315-9928868:-	UCEC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	2.0870e-05	-0.3238
chr1:9927315-9928868:-	UCS	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	8.7705e-04	0.4323
ENSG00000162441.10,LZIC	UCS	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	1.3143e-03	0.4188
ENSG00000162441.10,LZIC	UVM	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	2.4482e-08	-0.5779
chr1:9927315-9928868:-	UVM	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	2.0547e-08	-0.5805

Top

7. Enriched editing regions and drugs for LZIC

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000162441.10,LZIC	ACC	BAY.61.3606	EAG	4.4420e-03	0.3271
chr1:9927315-9928868:-	ACC	BAY.61.3606	EER	6.2257e-03	0.3152
ENSG00000162441.10,LZIC	BLCA	CGP.60474	EAG	2.6691e-05	-0.2086
chr1:9927315-9928868:-	BLCA	CMK	EER	5.0838e-07	-0.2486
ENSG00000162441.10,LZIC	BRCA	Bexarotene	EAG	1.8931e-02	0.0714
chr1:9927315-9928868:-	BRCA	Axitinib	EER	7.4383e-03	0.0815
chr1:9927315-9928868:-	CESC	BMS.536924	EER	9.2881e-09	-0.3250
ENSG00000162441.10,LZIC	CESC	BMS.536924	EAG	2.3580e-08	-0.3164
ENSG00000162441.10,LZIC	CHOL	Elesclomol	EAG	3.4256e-02	0.3754
chr1:9927315-9928868:-	CHOL	Elesclomol	EER	3.4873e-02	0.3742
ENSG00000162441.10,LZIC	COAD	CCT018159	EAG	7.5295e-03	-0.1620
chr1:9927315-9928868:-	COAD	JNJ.26854165	EER	4.0006e-03	-0.1746
chr1:9927315-9928868:-	ESCA	CGP.60474	EER	5.9759e-04	-0.2677
ENSG00000162441.10,LZIC	ESCA	CGP.60474	EAG	3.1591e-03	-0.2313
chr1:9927315-9928868:-	GBM	BIBW2992	EER	7.5849e-06	-0.3387
ENSG00000162441.10,LZIC	GBM	BIBW2992	EAG	7.5390e-06	-0.3388
ENSG00000162441.10,LZIC	HNSC	BAY.61.3606	EAG	5.7159e-09	0.2590
chr1:9927315-9928868:-	HNSC	BAY.61.3606	EER	2.6720e-10	0.2803
ENSG00000162441.10,LZIC	KIRC	MG.132	EAG	6.0597e-10	-0.3114
chr1:9927315-9928868:-	KIRC	MG.132	EER	4.1320e-10	-0.3143
chr1:9927315-9928868:-	KIRP	Epothilone.B	EER	2.1348e-03	0.1851
ENSG00000162441.10,LZIC	KIRP	Epothilone.B	EAG	2.2023e-03	0.1845
chr1:9927315-9928868:-	LAML	Metformin	EER	7.5612e-03	-0.2360
ENSG00000162441.10,LZIC	LAML	Metformin	EAG	7.5612e-03	-0.2360
ENSG00000162441.10,LZIC	LGG	BAY.61.3606	EAG	6.2068e-08	0.2329
chr1:9927315-9928868:-	LGG	BAY.61.3606	EER	6.2597e-08	0.2328
ENSG00000162441.10,LZIC	LIHC	AZD.0530	EAG	8.1241e-04	-0.1914
chr1:9927315-9928868:-	LIHC	AZD6244	EER	2.4647e-05	-0.2310
chr1:9927315-9928868:-	LUAD	CEP.701	EER	1.6274e-04	-0.1672
ENSG00000162441.10,LZIC	LUAD	CEP.701	EAG	4.1444e-04	-0.1564
chr1:9927315-9928868:-	LUSC	GW843682X	EER	4.9705e-02	-0.0887
ENSG00000162441.10,LZIC	MESO	Embelin	EAG	4.3796e-06	0.4827
chr1:9927315-9928868:-	MESO	Embelin	EER	8.5685e-06	0.4696
chr1:9927315-9928868:-	OV	Embelin	EER	3.3101e-10	0.3570
ENSG00000162441.10,LZIC	OV	Embelin	EAG	1.9410e-10	0.3614
chr1:9927315-9928868:-	PAAD	AZD6244	EER	1.6493e-03	-0.2376
ENSG00000162441.10,LZIC	PAAD	AZD6244	EAG	1.4650e-03	-0.2401
ENSG00000162441.10,LZIC	PCPG	Epothilone.B	EAG	2.6974e-03	0.2255
chr1:9927315-9928868:-	PCPG	Epothilone.B	EER	1.1473e-03	0.2438
ENSG00000162441.10,LZIC	PRAD	DMOG	EAG	2.7810e-04	0.1622
chr1:9927315-9928868:-	PRAD	DMOG	EER	5.7784e-05	0.1794
ENSG00000162441.10,LZIC	READ	Bortezomib	EAG	2.3257e-03	-0.3104
chr1:9927315-9928868:-	READ	Bortezomib	EER	2.5603e-03	-0.3076
ENSG00000162441.10,LZIC	SARC	BMS.536924	EAG	2.1022e-06	-0.2920
chr1:9927315-9928868:-	SARC	BMS.536924	EER	1.0459e-05	-0.2721
chr1:9927315-9928868:-	SKCM	GNF.2	EER	1.4800e-21	-0.4229
ENSG00000162441.10,LZIC	SKCM	GNF.2	EAG	1.9923e-21	-0.4217
chr1:9927315-9928868:-	STAD	BMS.708163	EER	2.2201e-03	-0.1590
ENSG00000162441.10,LZIC	STAD	BMS.708163	EAG	3.0955e-03	-0.1538
ENSG00000162441.10,LZIC	TGCT	Axitinib	EAG	1.6103e-02	-0.1969
chr1:9927315-9928868:-	TGCT	Axitinib	EER	1.2465e-02	-0.2049
chr1:9927315-9928868:-	THCA	Embelin	EER	1.4495e-14	0.3352
ENSG00000162441.10,LZIC	THCA	Embelin	EAG	5.1976e-13	0.3157
ENSG00000162441.10,LZIC	THYM	Embelin	EAG	1.0339e-11	0.5806
chr1:9927315-9928868:-	THYM	Embelin	EER	2.0370e-10	0.5515
ENSG00000162441.10,LZIC	UCEC	A.770041	EAG	6.5582e-19	-0.6143
chr1:9927315-9928868:-	UCEC	A.770041	EER	1.5514e-24	-0.6872
chr1:9927315-9928868:-	UCS	ABT.263	EER	3.9508e-03	0.3792
ENSG00000162441.10,LZIC	UCS	ABT.263	EAG	4.7496e-03	0.3720
chr1:9927315-9928868:-	UVM	Embelin	EER	7.7477e-06	0.4796
ENSG00000162441.10,LZIC	UVM	Embelin	EAG	7.6154e-06	0.4799

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType